DataMeds unit signs supply deal for six HHS peptides

DataMeds AI, Inc. (NASDAQ: MEDS) said on November 2, 2026 that its pharmacy-focused subsidiary Corexa Health has entered into an agreement for commercial supply of bulk drug substance and API for six peptides — BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. The company, headquartered in Tampa, Fla., posted the announcement through Access Newswire. Corexa Pharmacy intends to begin dispensing compounded peptide prescriptions in November 2026, the release says.

The move comes days after the Department of Health and Human Services published an enforcement-discretion policy for section 503A compounding of the same six peptide bulk drug substances (our report). Hims & Hers and Superpower had already previewed commercial peptide offerings after that notice (Hims; Superpower).

What the company says it will do

According to the release, Corexa Health’s deal covers commercial supply of bulk drug substance and API for the six named peptides. Interim Co-CEO Gerald Commissiong said HHS’s recent policy changes allow Corexa Pharmacy to dispense compounded versions of those peptides and allow the distribution division to use third-party logistics through a warehouse in Lakeland, Florida:

“HHS’ recent policy changes allow Corexa Pharmacy to dispense compounded versions of these Six Peptides and also allows our distribution division to leverage its third-party logistics (3PL) capabilities to help bulk drug substance and API to compliantly manage their supply via our strategically located warehouse in Lakeland, Florida.”

Commissiong also said relationships with manufacturers would help improve access for 503A compounding pharmacies in Corexa Health’s network of 6,500-plus independent pharmacies, and that the company sees pharmacy compounding as an alternative to unregulated research-use-only products sold online:

“This represents a significant opportunity for Corexa to give physicians a regulated, pharmacy-compounded option in place of the unregulated research-use-only products sold online. We believe that many gray market patients would prefer to purchase their peptides from a licensed pharmacy.”

DataMeds said it intends to use the Health Lives Here mobile application to help collect and report safety data under the HHS policy. The release says the products are compounded, are not FDA-approved, and have not undergone FDA evaluation for safety or efficacy.

How this relates to the HHS policy

HHS’s notice of availability was published in the Federal Register on October 30, 2026, at 91 FR 68526-68527 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496). The underlying policy, posted October 28, says HHS does not intend to take enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding Appendix A peptides — the same six named above — when listed conditions are met.

Those conditions, as we summarized from the policy text, include matching Appendix B identity and route limits; bulk from a section 510-registered, CGMP-compliant original manufacturer with facility location on a valid certificate of analysis; MedWatch reporting of serious adverse events and product-quality issues; a label stating the product is a compounded drug and not for resale; a single active pharmaceutical ingredient (no blends); documented oral bioavailability for oral forms; only an FDA 510(k)-cleared syringe as the delivery device; and a valid patient-specific prescription. The notice is non-binding; HHS may revisit the policy if a safety or quality signal arises. Written comments on the docket run for two weeks after publication; Foley & Lardner’s analysis, cited in our HHS coverage, puts that deadline at November 13, 2026.

Enforcement discretion is not FDA approval of finished peptide drugs, and it does not complete 503A bulks-list rulemaking.

The company’s PCAC claim — and what the record shows

DataMeds’ release describes the six peptides as ones “recommended by” FDA’s Pharmacy Compounding Advisory Committee at its July 23-24, 2026 meeting. That is the company’s framing. PCAC votes are advisory. Our July coverage reported that advisers backed those six substances for the 503A bulks list while FDA staff briefing documents recommended against all seven peptides then under review. Separately, HHS policy Appendix B states that FDA’s Center for Drug Evaluation and Research recommended against listing BPC-157, TB-500 and MOTS-c on the 503A bulks list even as PCAC voted in favor — a point we also noted in the Superpower story. None of that is a final bulks-list rule or an approval of compounded finished drugs.

Why it matters

DataMeds is a Nasdaq-listed company describing a supply-and-dispensing path for all six HHS Appendix A peptides, plus a 3PL role aimed at independent 503A pharmacies and an app-based safety-reporting plan. That sits alongside earlier post-notice commercial moves by Hims (waitlist) and Superpower (pre-orders). It does not settle rulemaking, state-board practice or whether Corexa will meet every listed HHS condition when it begins dispensing.

What is not known

• The identity of the bulk/API supplier and the commercial terms of the supply agreement (the release does not name the counterparty).
• Whether Corexa Pharmacy will dispense in every state, and on what timeline in November 2026.
• How the Health Lives Here app will feed MedWatch or state reporting in practice.
• Whether HHS will revise or withdraw the interim policy before or after the November 13 comment close.

What to watch

Corexa’s first dispensed compounded peptide prescriptions; docket comments on HHS-OASH-2026-0496 through November 13; any FDA 503A bulks-list rulemaking under RIN 0910-ZD94; and further commercial responses from telehealth and pharmacy networks.